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A dissolution method was developed for combination of two drugs which are already marketed as an individual product, 
Clopidogrel Bisulfate Tablets USP 75 mg and another is Rivaroxaban Tablets 10 mg & 20 mg. It was emphasized that both 
products have several advantages when given as combination therapy. Hence, the preference was given to develop a single 
dissolution method for the analysis of both the active components. This article presents a single dissolution method to 
accommodate both drugs. The method uses USP Type II Apparatus (paddles) at 75 rpm in 1000 mL of Acetate buffer (pH 
4.5) medium containing 1% Sodium Lauryl Sulfate as surfactant at 37 °C± 0.5°C . This dissolution methodology provides 
good dissolution profiles for both Clopidogrel Bisulfate and Rivaroxaban and is able to discriminate the changes in 
composition, manufacturing process and stability for the combination tablets. To quantitate both drugs simultaneously, a 
rapid isocratic reversed-phase liquid chromatographic method was developed and validated.  
Keywords: Dissolution, Method development, Validation, HPLC, Rivaroxaban, Clopidogrel Bisulfate, Tablet, Sink 
condition 
 
INTRODUCTION 
Clopidogrel Bisulfate Tablet is an adenosine diphosphate 
receptor inhibitor that prevents platelets in the blood from 
sticking together and forming clots [1, 2]. The empirical 
formula of Clopidogrel Bisulfate is C16H16Cl NO2S•H2SO4 and 
its molecular weight is 419.9. Clopidogrel Bisulfate, USP is a 
white to off-white powder. Clopidogrel Bisulfate tablets, 
contains 97.875 mg of Clopidogrel bisulfate which is the molar 
equivalent of 75 mg of Clopidogrel base [3,4].Clopidogrel 
Bisulfate is fairly soluble and stable in aqueous solution at low 
pH, however solubility drops steeply when the solution of  pH 
is above 3. Clopidogrel bisulfate exhibits poor dissolution in 
the pH range of 4.5 to 6.8 [5]. Rivaroxaban is used for 
prophylaxis of deep vein thrombosis (DVT), which may lead to 
pulmonary embolism (PE), in adults undergoing hip and knee 
replacement surgery as well as Rivaroxaban is used for stroke 
prophylaxis in patients with non-valvular atrial fibrillation [6, 
7]. It is a white to yellowish powder with a molecular weight of 
435.89. Rivaroxaban is practically insoluble in water and 
aqueous media with pH 1 – 9 (pH – independent, 5 – 7 mg/L 
are soluble at 25 °C) . It can be classified as a Class II 
substance in the Biopharmaceutics Classification System (low 
solubility, high permeability) [8]. The addition of very low 
dose anticoagulation with Rivaroxaban may represent a new 
treatment strategy in patients with a recent acute coronary 
syndrome. A recent published trial found that a low dose 
Rivaroxaban to optimal antiplatelet therapy reduces mortality, 
cardiovascular mortality, infarct or stroke without significantly 
increasing fatal bleeding [9]. Hence it was decided to develop 
an in-vitro dissolution method for combination of Clopidogrel 
and Rivaroxaban Tablets for academic study purpose. 
 
Dissolution is a physical test to predict the drug release from a 
dosage form for some precise time. Fundamentally, this process 
is controlled by the affinity between the solvent and the solid 
substance and the way by which the pharmaceutical system 
releases the drug. According to Mehta and coworkers 
dissolution test provides an indication of bioavailability of a 
drug and, thus, pharmaceutical equivalence from batch to 
batch. The dissolution test is an important tool in quality 
control of drugs and it becomes more important for drugs with 
relatively low water solubility [10, 11, 12]. 
 
FDA suggests that  by using predictive mathematical model, 
the relationship between an in vitro property of the dosage 
forms and an in vivo response can be established. The concept 
behind establishing an IVIVC is that in vitro dissolution can 
serve as a surrogate for pharmacokinetic studies in humans, 
which may reduce the number of bioequivalence studies 
performed during the initial approval process e.g. a products 
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having multiple strengths as well as when certain scale-up and 
post-approval changes in the formulation need to be made[13]. 
 A dissolution method should be discriminatory, and it should 
allow evaluating the performance of the product and possible 
changes it may suffer during routine commercial production 
and from stability studies. Many variables can influence the 
results of a dissolution test. Among these variables, we can find 
solubility, chemical nature of the drug, the dosage form, 
excipients and manufacturing technology employed, the 
apparatus used, the stirring speed, the use of devices for dosage 
forms (sinkers), the volume of media used, pH and temperature 
of the media, the filtration, and analytical method employed 
[14]. If the developed dissolution method mimics the GI-tract 
environment with discriminating power, it can be useful to 
forecast the in vivo behavior of formulations and to 
characterize the in vitro dissolution profiles of drug products 
during pharmaceutical development [15-19].  
 
The Biopharmaceutics Classification System groups drugs into 
four classes. The class II category, low solubility and high 
permeability drugs are identified as potential drug candidates 
for investigation. The low solubility aspects can be handled in 
order to develop a bio-relevant and discriminating method for 
dissolution [20-24]. The development of a meaningful 
dissolution procedure for drug products with limited water 
solubility has been a challenge to both the pharmaceutical 
industry and the regulatory agencies [25]. Clopidogrel belongs 
to Class II (low solubility/high permeability), and its absorption 
in the gastrointestinal tract might be limited by the dissolution 
rate [26, 27, 28]. Compounds belonging to Class II are eligible 
to establish a significant in vitro/in vivo correlation (IVIVC), 
hence the appropriate selection for dissolution study’s 
conditions is essential to have a method able to discriminate 
between products with potential problems of bioavailability. In 
vitro dissolution study is an official test of pharmacopoeias for 
evaluation of drug release from solid and semisolid dosage 
forms and to establish in vitro/in vivo correlation. It is also 
routinely used tool in Quality Control (QC) to ensure batch to 
batch consistency and in Research and Development (R&D) to 
provide some predictive estimate of the drug release in respect 
to the In vivo performance. When dissolution test is not defined 
in the monograph of the dosage form, or if the monograph is 
not available, comparison of drug dissolution profiles is 
recommended in dissolution media, in the pH range of 1.2–7.5. 
Drug solubility and solution stability are important properties 
to be considered when selecting the dissolution medium. In this 
study, the first approach was to compare buffers of different 
pH, as commonly used for solid dosage forms. The stirring 
speed selection was done based on the range recommended 
(50–75 rpm) for apparatus 2   
Different analytical methods like colorimetric method, RP 
HPLC method and bio analytical method for estimation of 
Rivaroxaban [29-32].Several spectrophotometric and high 
performance liquid chromatographic (HPLC) methods have 
been reported for the separation and quantitation of Clopidogrel 
or Pravastatin in biological fluids and drug product [33-37]. 
The present investigation was taken up to develop a suitable 
dissolution profile for the Rivaroxaban and Clopidogrel tablets 
combination in its dosage form, estimate and validate it by 
using RP-HPLC methods.  
For immediate release products, dissolution method should 
confirm to one of the several methods currently specified for 
the dissolution requirement in USP. The volume of the 
dissolution medium is generally 500, 900, or 1000 ml. Sink 
conditions are desirable but not mandatory [13].Actually  the 
volume of dissolution medium to be used is defined 
considering "sink condition." The solubility of the drug 
substance is quantitatively determined in several dissolution 
media within the physiological pH range at 37 °C. Using this 
value, the volume of dissolution medium necessary to obtain a 
saturated solution of the highest dose of the product to be 
marketed is calculated. Sink condition is considered as at least 
3 times this volume. Some companies work with 5 times or 10 
times this value. There are some instances where the 
dissolution test is more discriminative if sink condition is not 
followed.[41]. 
For water insoluble or sparingly water soluble drug products, 
use of a surfactant such as sodium lauryl sulfate is 
recommended[38]. Due to the poor solubility of Rivaroxaban 
in water, using a surfactant such as sodium lauryl sulfate is 
essential[32]. 
Typical specification should range from 70 to 85 % at 
dissolution times between 30 and 60 minutes, specifications in 
excess of 85% are inappropriate since allowance must be made 
for assay and content uniformity of the formulation [39]. As 
per USFDA guideline, for poorly water soluble drug at two-
point dissolution study, one at 15 minutes and the other at a 
later point (30, 45 or 60 minutes) to ensure 85 % dissolution is 
recommended [13].  The dissolution specification is expressed 
as the quantity Q of the active substance as a percentage of the 
content stated on the product label, which is dissolved in a 
specified time frame. As per British Pharmacopoeia unless 
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otherwise specified, the value of Q is 75 percent. In most cases 
when tested under reasonable and justified test conditions at 
least 75 % of the active substance is released within 45 
minutes. Typically, one limit is specified to ensure that most of 
the active substances are dissolved within the preset time 
period[4]. 
 
MATERIALS AND METHODS  
A HPLC SPD- 20AT (Shimadzu) equipped with detector SPD- 
20AT, pump LC-20AT, injector: Rheodyne injector (20 µl 
Capacity), syringe: Hamilton (25 µl) and chromatographic 
software: Spinchrom was used for the study purpose. Other 
equipments used for the study are pH Meter from Chemiline, 
India, Ultasonicsonicator from Toshcon, Toshniwal process 
instrument pvt. Ltd. Ajmer, Analytical Balance: AX 200 etc. 
Manual Dissolution Apparatus Electro lab 
 
Preparation of Dissolution Medium: 
Dissolve 2.99g of Sodium acetate trihydrate to 1000mL of 
water. Adjust the pH to 4.5± 0.05 with glacial acetic acid. Add 
10 gm Sodium lauryl sulfate to this buffer and mix well. 
Dissolution conditions 
Dissolution Medium: pH 4.5 Acetate buffer with 1.0% SLS 
Medium Volume: 1000ml 
Agitation:75 RPM 
Apparatus :USP TypeII (Paddle) 
Time Point:60 minutes 
Temperature: 37.5 C± 0.5 °C 
Withdrawal volume:10ml 
Chromatographic conditions: 
Column:  BDS hypersil C18, 250mm × 4.6mm, 5µ(particle 
size), Thermo scientific 
Flow rate : 1.0ml/mint 
Injection volume:20µ 
Column Oven temp: Room Temp 
Wavelength:220nm 
Run Time: 10 minutes 
 
Preparation of mobile phase: 
It is the mixture of buffer and methanol in ratio of 30:70. 
Preparation of Buffer for mobile phase: 
Buffer 0.05M potassium di hydrogen ortho phosphate 
buffer pH 4.0. 
Dissolve 6.8gm potassium di hydrogen ortho phosphate buffer 
in 800ml water and dissolve. Adjust pH 4.0 of this solution 
with 1% ortho phosphoric acid (H3PO4) and make up volume 
up to 1000ml with water.  
Mobile phase: 
Mix Buffer 0.05M potassium di hydrogen ortho phosphate 
buffer pH 4.0 and methanol in ratio 30:70. 
 
Preparation of standard solution for dissolution: 
Standard Stock Preparation: 
Take 22mg Rivaroxaban working standard and 97.8mg 
Clopidogrel Bisulfate working standard into a 100 ml flask. In 
this flask 20ml methanol is added and sonicated for 10 minutes. 
Once the standards are dissolved make up the volume up to 
100ml with methanol. 
Standard preparation: 
Further take 10ml from this solution to a 100ml volumetric 
flask. Make up with dissolution medium. (use this solution for 
std) (22ppm Rivaroxaban, 97.8ppm Clopidogrel Bisulfate) 
Preparation of Test solution for dissolution: 
Transfer one tablet in each of the dissolution vessel containing 
dissolution medium pre-equilibrated to 37.5 C± 0.5 °C. Run the 
dissolution apparatus as per the above dissolution conditions. 
At specified time interval, withdraw 10ml of the sample aliquot 
from each of the dissolution vessel and replace with fresh 
dissolution media. Filter the sample aliquot through Whatman 
filter paper one, discarding few ml of filtrate, inject the sample 
into chromatographic system. 
 
Chromatogram of Placebo 
 
Chromatogram of System Suitability Solution 
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Chromatogram of Test Solution 
 
 
RESULT  & DISCUSSION 
From the dissolution studies, it was observed that solubility of 
Rivaroxaban is very low at all physiological pH range 1.2 to 
6.8; example in dissolution medium0.1N HCl pH1.2, Acetate 
buffer pH 4.5 and Phosphate Buffer pH 6.8.Rivaroxaban was 
not released completely in all the range tested, it also showed 
pH independent release profile. Whereas Clopidogrel Bisulfate 
released more than 90 %  in acidic pH  but it has less 
dissolution profile at pH 4.5 and pH 6.8 Phosphate buffer. 
Hence it was desirable to increase the solubility of both the 
drug at one physiological pH condition to get complete 
dissolution profile. We have selected pH 4.5 Acetate buffer for 
further study. To increase the solubility, it is decided to add 
surfactant in the dissolution medium. 
 
It is observed that with 0.2 % SLS and 0.5 % SLS at 75 rpm 
drug release was less for Clopidogrel Bisulfate.  At 1% SLS 
with 50 rpm dissolution was satisfactory but small variation 
was observed for individual unit, at initial stage Relative 
Standard Deviation (RSD) was found higher with 50 rpm. This 
may be due to less hydrodynamic properties of the dissolution 
medium at 50 rpm. It was well mentioned that at 50 rpm there 
is a chance of variation for a few products. Hence with 1 % 
SLS at 75rpm dissolution was carried out and found that more 
than 90 % drug release was observed in 60 minutes and sink 
condition is achieved. Based on the results obtained above, it 
was selected as discriminative dissolution test conditions for 
Rivaroxaban and Clopidogrel tablet combination and validated. 
The proposed HPLC method was simple, accurate, and 
reproducible for routine analysis of Clopidogrel and 
Rivaroxaban in dissolution test medium and in dosage forms. 
The results of this study showed that Rivaroxaban is unstable in 
almost all stress degradation conditions. The proposed stability-
indicating method could be used for the determination of 
Rivaroxaban and Clopidogrel in the presence of tablet 
excipients and also degradation products. Since there is no 
official method for Rivaroxaban and Clopidogrel tablets 
combination, the developed method could be used for quality 
control purposes. 
 
CONCLUSION: 
The dissolution test developed and validated for Rivaroxaban 
and Clopidogrel tablets (20mg & 75 mg) and found 
satisfactory. The dissolution conditions for this combination 
were 1000ml of acetate buffer pH 4.5 with 1% SLS at 37°C± 
0.5 °C, USP Type II (paddle) apparatus,75 rpm stirring speed 
& filtration with easily available Whatman filter paper 1. The 
drug delivery was higher than 90 % within 60 min for all 
evaluated samples/products fulfilling the pharmacopeial 
guidelines for conventional solid oral tablet dosage form. More 
over this condition satisfied the criteria of drug stability during 
dissolution study. This method was validated to ensure that 
proposed method is linear, precise, accurate, sensitive, robust 
and cost effective. This can be used for dissolution study of this 
combination product in routine quality control successfully. 
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